vitaMedMD® and TherapeuticsMD® are registered
trademarks and BocaGreenMD™ is a trademark of TherapeuticsMD, Inc.
Duavee™ is a trademark of Pfizer, Inc.
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding Dr.
Mirkin’s appointment as the company’s Chief Medical Officer, the
opinions of Dr. Mirkin, Mr. Finizio, and Dr. Archer with respect to what
Dr. Mirkin’s experience and expertise will signal or achieve for the
company, its portfolio of products, its platform, its role in the
women’s hormone and health market, and its commitment to the development
of novel hormone replacement therapy for women, the company’s intention
to introduce FDA-approved products that match the molecular structure of
the estradiol and/or progesterone hormones produced in a women’s body,
the company’s focus, the company’s commitment to the development of
advanced hormone therapy pharmaceutical products that fill a critical
and long-ignored need in the hormone and women’s health market, the
anticipated achievements, attributes, and benefits of TX 12-001-HR, what
the REPLENISH clinical trial is designed to evaluate, and statements
regarding other hormone technology that the company is currently
evaluating are forward-looking statements within the meaning of the
“safe harbor” provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including but not limited to: timely and successful completion of
clinical studies and the results thereof; risks and uncertainties
associated with the company’s business and finances in general; and
other risks detailed in the company’s filings with the U.S. Securities
and Exchange Commission including its annual report on Form 10-K,
reports on Form 10-Q and Form 8-K, and other such filings. These
forward-looking statements are based on current information that may
change. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in their
entirety by this cautionary statement, and the company undertakes no
obligation to revise or update any forward-looking statement to reflect
events or circumstances after the issuance of this press release.
Dan Cartwright, 561-961-1930
In-Site Communications, Inc.
Lisa M. Wilson,
Red Fox Communications
Judy Grossman, 917-913-1690
Source: TherapeuticsMD, Inc.